Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro

Cancer Letters

Volumn 203, Issue 2, 2004, Pages 155-161

  Chung, Jinsoo ^a   Kwak, Cheol ^b   Jin, Ren Jie ^c   Lee, Chang Ho ^d   Lee, Kang Hyun ^a   Lee, Sang Eun ^b  

^a National Cancer Center   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Soonchunhyang University   (South Korea)

Author keywords

Anti sense; Bladder cancer; Chemosensitivity; Cisplatin; Clusterin

Indexed keywords

CASPASE 3; CISPLATIN; CLUSTERIN; DNA FRAGMENT; MESSENGER RNA; PLASMID VECTOR;

APOPTOSIS; ARTICLE; BIOASSAY; BLADDER CANCER; CANCER CELL; CELL DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 0346724931     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.07.008     Document Type: Article

References (28)

1. Thurman S.A., De Weese T.L. Multimodality therapy for the treatment of muscle-invasive bladder cancer. Semin. Urol. Oncol. 18:2000;313-322.
2. Roth B.J., Bajorin D.F. Advanced bladder cancer: the need to identify new agents in the post M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin). World J. Urol. 153:1995;894-900.
3. Sternberg C.N., Calabro F. Chemotherapy and management of bladder tumors. BJU Int. 85:2000;599-610.
4. Jones S.E., Jomary C. Clusterin. Int. J. Biochem. Cell Biol. 34:2002;427-431.
5. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 27:1995;633-645.
6. Kyprianou N., English H.F., Davison N.E., Issac J.T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 51:1991;162-166.
7. Wright P.S., Cross-Doersen D., Th'ng J.P., Guo X.W., Crissman H.A., Bradbury E.M., Montgomery L.R., et al. A ribonucleotide reductase inhibitor, MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exp. Cell Res. 222:1996;54-60.
8. Schwochau G.B., Nath K.A., Rosenberg M.E. Clusterin protects against oxidative stress in vitro through aggressive and nonaggressive properties. Kidney Int. 53:1998;1647-1653.
9. French L.E., Wohlwend A., Sappino A.P., Tschopp J., Schifferli J.A. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J. Clin. Invest. 93:1994;877-884.
10. Viard I., Wehrli P., Jornot L., Bullani R., Vechietti J.L., Schifferli J.A., Tschopp J., French L.E. Clusterin gene expression mediates resistance to apoptotic cell death induced by heat shock and oxidative stress. J. Invest. Dermatol. 112:1999;290-296.
11. Lee C., Janulis K., Ilio A., Shah I., Park S., Kim V., Cryns M., Pins R. In vitro models of prostate apoptosis: clusterin as an antiapoptotic mediator. Prostate Suppl. 9:2000;21-24.
12. Steinberg J., Oyasu R., Lang S., Sintich S., Rademaker A., Lee C., Kozlowski J.M., Sensibar J.A. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 3:1997;1707-1711.
13. Miyake H., Nelson C., Rennie P.S., Gleave M.E. Testosterone-repressed prostate message -2 is an antiapoptotic gene involved in progression to androgen-independence in prostate cancer. Cancer Res. 60:2000;170-176.
14. Miyake H., Hara S., Arakawa S., Kamidono S., Hara I. Over expression of clusterin is an independent prognostic factor for nonpapillary renal cell carcinoma. J. Urol. 167:2002;703-706.
15. Miyake H., Gleave M.E., Arakawa S., Kamidomi S., Hara I. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potentials. J. Urol. 167:2002;2003-2008.
16. Redondo M., Villar E., Torres-Munoz J., Tellez T., Morell M., Petito C.K. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 157:2000;393-399.
17. Zellweger T., Miyake H., July L.V., Akbari M., Kiyama S., Gleave M.E. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptic gene clusterin. Neoplasia. 3:2001;360-367.
18. Gleave M.E., Miyake H., Zellweger T., Chi K., July L., Nelson C., Rennie P. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology. Suppl. 58:2001;39-49.
19. Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., et al. Methtrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of urothelium. Efficacy, patterns of response and relapse. Cancer. 64:1989;2448-2458.
20. Marshall J.L., Andrews P.A. Preclinical and clinical experience with cisplatin resistance. Hemat. Oncol. Clin. Nor. Am. 9:1995;415-427.
21. Vaughan D.J., Malkowiccz S. Recent advances in bladder cancer chemotherapy. Cancer Investig. 19:2001;77-85.
22. Chu G., Mantin R., Shen Y.M., Baskett G. Massive cisplatin overdose by accidental substitution for carboplatin: toxicity and management. Cancer. 72:1993;3707-3714.
23. Vogelzang N.J., Stadler W.M. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 53:1999;243-250.
24. Sintich S.M., Steinberg J., Kozlowski J.M., Lee C., Pruden S., Sayeed S., Sensibar J.A. Cytotoxic sensitivity to tumor necrosis factor-alpha in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (clusterin). Prostate. 29:1999;87-93.
25. Humphreys D., Hochgrebe T.T., Easterbrook-Smith S.B., Tenniswood M.P., Wilson M.R. Effects of clusterin overexpression on TNFalpha- and TGFbeta-mediated death of L929 cells. Biochemistry. 36:1997;15233-15243.
26. Miyake H., Hara I., Yamanaka K., Arakawa S., Kamidino S. Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J. Urol. 162:1999;2176-2178.
27. Hong J.H., Lee E., Hong J., Shin Y.J., Ahn J. Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int. 90:2002;113-117.
28. Miyake H., Hara I., Kamidono S., Gleave M.E. Synergistic chemosensitization and inhibition of tumor growth and metastasis by antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7:2001;4245-4252.